Our team knows eye care

We have assembled a team with extensive experience developing and commercializing leading ophthalmic products and therapies.

JEFFREY NAU, PHD, MMS President and Chief Executive Officer

Jeffrey Nau, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medial Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.

daniel lochner

Daniel Lochner, MBA

Chief Financial Officer

Daniel has nearly 15 years of experience in healthcare investing. Prior to joining Oyster Point Pharma, Daniel held positions of increasing responsibility in equity investing and fund management at Goldman Sachs Asset Management. Most recently he was a Managing Director and Portfolio Manager at Goldman Sachs, where he was a healthcare equity investor for various fund strategies. As a healthcare investor, Daniel focused on biotechnology, pharmaceutical, medical device and healthcare services companies and invested in a range of therapeutic categories, including ophthalmology. Daniel received an Executive M.B.A. from Columbia University and a B.A. in Economics from the University of Richmond.

John Snisarenko

John Snisarenko, MBA

Chief Commercial Officer

John has 30 years of commercial experience in the pharmaceutical industry, including major ophthalmology businesses. He has a proven track record in taking programs from development to successful commercialization, and helping businesses achieve high growth. Prior to joining Oyster Point, John spent the past 2 years at Shire (now Takeda) as Group Vice President and Head of its ophthalmic business. During that time, he led a large, multidisciplinary team accountable for the growth of Shire’s first ophthalmic therapeutic, Xiidra ®, for treatment of dry eye. He served as a member of the commercial leadership team at Shire and played a key role in the divestiture of the ophthalmic business to Novartis Pharma. Prior to joining Shire, John led commercial activities for Genentech’s ophthalmology (Lucentis ®) and rheumatology (Rituxan ®, Actemra ®) franchises for 10 years. John has also held various positions of increasing responsibility at CIBA Vision/Novartis Pharma. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.

Loni Da Silva, MS, RAC

Vice President of Regulatory Affairs

Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to the ophthalmic space, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.

Dawn Pruitt Koffler, MBA

Dawn Pruitt Koffler, MBA

Vice President of Marketing

Dawn has over 15 years of experience in sales and marketing for pharmaceutical products and medical devices. Prior to joining Oyster Point, she spent 12 years at Allergan where she served as Executive Director for consumer eye care, which included the TrueTear® device and Refresh® brands. Before that, Dawn was Executive Director of Strategic Marketing, responsible for leading the commercial strategy for the eye care pipeline, and led consumer marketing for Restasis®, which earned her recognition as a Top 25 DTC marketer. She was also a member of the Global Eye Care R&D Governance Board and was the commercial lead for the integration of Oculeve and ForSight VISION5. Dawn holds a B.S. in physical therapy from California State University, Long Beach and an M.B.A. from the University of Notre Dame.

George Donato

George Donato, MBA

Vice President of CMC

George is an accomplished Pharmaceutical Operations and Technical CMC executive with over 25 years delivering exceptional results in new product launches, product development and supply chain. Most recently he was the Sr. Vice President, Global Operations for Iroko Pharmaceuticals and prior to that he was a New Product Leader at Pfizer. He has successfully launched several new products globally for Iroko, Pfizer and Wyeth. George is adept at balancing regulatory, quality, technical, supply and commercial needs to continuously improve process performance, quality and profitability. George graduated from Widener University with an M.B.A. and a B.S. in Engineering.